Obstructive Lung Disease

Obstructive lung disease is not a single diagnosis. It’s a family of conditions that share one defining feature: the airways themselves narrow, whether from inflammation, reactive muscle tightening, structural damage, or mucus buildup, making it harder to move air out of the lungs than to move it in. Asthma and COPD are the two largest members of this family by far, but several other distinct conditions, emphysema, alpha-1 antitrypsin deficiency, bronchiectasis, and exercise-induced bronchoconstriction, belong to it too. This guide organizes the family, explains how its members relate to and differ from one another, and points to where each is covered in full depth.

What “Obstructive” Means

Spirometry, the core lung function test, measures how much air you can forcefully exhale and how quickly. The key number in an obstructive pattern is a reduced ratio between how much air comes out in the first second of a forced exhale and the total amount you exhale, meaning air is moving out of the lungs more slowly than it should. That’s different from a restrictive pattern, where the lungs simply can’t hold or expand to a normal volume in the first place. Every condition on this page produces some version of an obstructive pattern, though the underlying reason, and how reversible it is, varies a great deal from one condition to the next. Pulmonary function testing builds on basic spirometry with additional measurements when a more complete picture is needed.

Asthma and COPD: The Two Major Diagnoses

Asthma

Chronic airway inflammation and reactivity that produces episodic wheezing, cough, chest tightness, and shortness of breath, commonly triggered by allergens, exercise, respiratory infections, or irritants. Airflow obstruction is usually substantially reversible with a bronchodilator.

COPD

Progressive, largely fixed airflow limitation, most often related to a significant smoking or occupational exposure history, that encompasses two overlapping patterns: chronic bronchitis and emphysema. Symptoms tend to be more persistent day to day than asthma's episodic pattern.

Because both conditions cause similar day-to-day symptoms and both are diagnosed with spirometry, they’re genuinely easy to confuse, including at times in casual conversation about lung disease. The clearest distinguishing clue is usually how the airflow limitation behaves: asthma’s is typically variable, sometimes near-normal one day and significantly reduced the next, and often improves substantially after a bronchodilator, while COPD’s is generally steadier and only partially reversible. Age of onset and smoking or exposure history add further clues, though neither is an absolute rule; asthma can be diagnosed for the first time in an older adult, and COPD can occur without any smoking history at all, including as a consequence of alpha-1 antitrypsin deficiency. Some patients genuinely have overlapping features of both conditions, sometimes described as asthma-COPD overlap, which calls for an individualized treatment plan rather than a strict either-or diagnosis.

This is a working summary, not the full picture. Our dedicated Asthma vs. COPD comparison walks through each distinguishing factor in more depth, including what asthma-COPD overlap looks like in practice and how a physician sorts the two apart using history and spirometry together.

COPD’s Two Faces: Emphysema and Alpha-1 Antitrypsin Deficiency

COPD is an umbrella term, not a single structural disease, and two of its most important components each get their own page in our library. Emphysema is the structural pattern of permanent damage to the air sacs, or alveoli, that reduces the lung’s elastic recoil and its ability to transfer oxygen into the blood; it commonly overlaps with chronic bronchitis, the other classic COPD pattern, in the same patient rather than existing as a fully separate condition. Alpha-1 antitrypsin deficiency is different in kind: it’s an inherited condition in which the body doesn’t produce enough functional alpha-1 antitrypsin, a protein that normally protects lung tissue from damage, leading to early-onset emphysema and, in some genotypes, liver disease. It’s a genuinely testable, specific genetic cause of COPD, and current guidance supports testing patients diagnosed with COPD or emphysema at an unusually young age, without a heavy smoking history, or with a family history of early lung or liver disease, since a positive result changes management and prompts screening for relatives.

When Asthma Doesn’t Respond: Severe and Eosinophilic Asthma

Most asthma is well controlled with standard inhaled therapy, but a meaningful subset of patients isn’t, and that subset has its own evaluation pathway rather than simply “more of the same medication.” Severe asthma describes asthma that remains uncontrolled despite optimized high-dose inhaled treatment, with adherence and inhaler technique confirmed and contributing comorbidities addressed, or asthma that requires that level of treatment just to stay controlled at all. Before that label is applied, it’s worth ruling out the far more common explanations for asthma that seems hard to control, including inhaler technique, adherence, and unaddressed triggers, which is exactly what a careful evaluation is for.

Within severe asthma, a specific and clinically useful pattern is eosinophilic asthma, a phenotype driven by type 2, eosinophilic airway inflammation and identified through blood eosinophil counts and FeNO testing alongside symptom and exacerbation history. Identifying this phenotype matters because it’s the group most likely to benefit from asthma biologics, a class of injectable medications that target specific inflammatory pathways, including IgE, IL-5, IL-4/IL-13, and TSLP, in patients whose asthma remains poorly controlled despite optimized inhaled therapy.

Bronchiectasis: A Different Kind of Obstruction

Bronchiectasis belongs in this family because it produces an obstructive pattern on spirometry, but its underlying problem is structural rather than inflammatory or reactive: the airways become permanently widened and damaged, which lets mucus pool instead of clearing normally and predisposes to recurrent respiratory infection. That structural difference is exactly why its treatment looks different from asthma’s or COPD’s. Rather than centering on inhaled anti-inflammatory or bronchodilator therapy, bronchiectasis management centers on daily airway clearance, techniques and devices that physically help mobilize and clear mucus, with antibiotics reserved for exacerbations and, for a subset of patients with frequent flare-ups, longer-term suppressive strategies.

Exercise-Induced Bronchoconstriction

Exercise-induced bronchoconstriction is transient narrowing of the airways triggered specifically by physical exertion, producing cough, wheeze, chest tightness, or breathlessness during or shortly after exercise. It’s worth calling out as its own entity because it doesn’t require an underlying asthma diagnosis; some people have it as an isolated finding, while others have it as one manifestation of established asthma. Either way, it’s a distinct, recognizable, and treatable pattern rather than simply being “out of shape.”

How Obstructive Lung Disease Is Diagnosed

Spirometry is the starting point for nearly every condition on this page, since it’s what actually documents an obstructive pattern and, through bronchodilator response, helps distinguish asthma’s typically reversible obstruction from COPD’s more fixed pattern. Broader pulmonary function testing adds further detail when needed, and more specialized tests, including exhaled nitric oxide and airway challenge testing, help characterize airway inflammation and reactivity in patients where the diagnosis or phenotype isn’t yet clear. High-resolution chest CT is the key imaging test for confirming bronchiectasis specifically, and a simple blood test confirms or rules out alpha-1 antitrypsin deficiency. A cough lasting more than eight weeks, our definition of chronic cough, is one of the more common symptoms that prompts this whole workup in the first place, since it can be the presenting sign of asthma, COPD, or bronchiectasis alike.

How Obstructive Lung Disease Is Treated

Treatment across this family shares some common building blocks and diverges in others, matched to each condition’s underlying mechanism. Inhaled therapy is central to asthma and COPD alike, and getting real benefit from it depends heavily on using the right device correctly, a step that’s easy to underestimate and genuinely changes how much medication actually reaches the airways. Asthma treatment emphasizes inhaled anti-inflammatory therapy, with biologics reserved for the severe, eosinophilic-driven subset described above; COPD treatment emphasizes inhaled bronchodilator therapy, with an inhaled corticosteroid added for select patients with frequent exacerbations. Bronchiectasis, as covered above, is managed primarily through daily airway clearance rather than inhaled anti-inflammatory therapy. For both asthma and COPD, a written asthma action plan or COPD action plan helps a patient recognize the early signs of a worsening flare and know exactly how to respond, rather than waiting until symptoms have progressed to the point of needing urgent or emergency care.

Getting Evaluated

If you have ongoing wheeze, a cough that has lasted more than eight weeks, breathlessness that has changed from your baseline, or frequent respiratory infections, a pulmonary evaluation is a reasonable next step. That evaluation typically starts with a detailed history and spirometry, and expands from there based on what the initial findings suggest, whether that’s confirming asthma or COPD, checking for alpha-1 antitrypsin deficiency, imaging to evaluate for bronchiectasis, or a closer look at symptoms specifically tied to exercise.